Titan Pharmaceuticals, Inc. (de) (TTNP) gains 2.17% for July 21

Equities Staff  |

Titan Pharmaceuticals, Inc. (de) (NASDAQ: TTNP) shares gained 2.17%, or $0.05 per share, to close Wednesday at $2.35. After opening the day at $2.30, shares of Titan, (de) fluctuated between $2.36 and $2.30. 52,909 shares traded hands a decrease from their 30 day average of 144,780. Wednesday's activity brought Titan, (de)’s market cap to $23,180,560.

Titan, (de) is headquartered in South San Francisco, California..

About Titan Pharmaceuticals, Inc. (de)

Titan Pharmaceuticals, Inc., based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Visit Titan Pharmaceuticals, Inc. (de)’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Titan Pharmaceuticals, Inc. (de) and to follow the company’s latest updates, you can visit the company’s profile page here: Titan Pharmaceuticals, Inc. (de)’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content